The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib
°áÇÙ¹×È£Èí±âÁúȯ 2015³â 78±Ç 4È£ p.315 ~ p.320
¹Úµ¿ÀÏ(Park Dong-Il) - Chungnam National University Hospital Department of Internal Medicine Division of Pulmonary
±è¼±¿µ(Kim Sun-Young) - Chungnam National University Hospital Department of Internal Medicine
±èÁÖ¿Á(Kim Ju-Ock) - Chungnam National University Hospital Department of Internal Medicine
¹ÚÈñ¼±(Park Hee-Sun) - Chungnam National University Hospital Department of Internal Medicine Division of Pulmonary
¹®À翵(Moon Jae-Young) - Chungnam National University Hospital Department of Internal Medicine Division of Pulmonary
Á¤Àç¿í(Chung Chae-Uk) - Chungnam National University Hospital Department of Internal Medicine Division of Pulmonary
±è¼º¼ö(Kim Song-Soo) - Chungnam National University Hospital Department of Radiology
¼ÀçÈñ(Seo Jae-Hee) - Chungnam National University Hospital Department of Preventive Medicine
ÀÌÁ¤Àº(Lee Jeong-Eun) - Chungnam National University Hospital Department of Internal Medicine
Á¤¼º¼ö(Jung Sung-Soo) - Chungnam National University Hospital Department of Internal Medicine Division of Pulmonary
Abstract
Background : The efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy can be measured based on the rate of treatment response, based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria or progression-free survival (PFS). However, there are some patients harboring sensitive EGFR mutations who responded poorly to EGFR-TKI therapy. In addition, there is variability in the PFS after EGFR-TKI treatment.
Materials and Methods : We performed a retrospective analysis of the medical records of 85 patients with non-small cell lung cancer, who had achieved a stable disease or better response at the first evaluation of treatment response, after receiving a 2-month course of gefitinib. We calculated the tumor shrinkage rate (TSR) by measuring the longest and perpendicular diameter of the main mass on computed tomography before, and 2 months after, gefitinib therapy.
Results : There was a significant positive correlation between the TSR and PFS (R=0.373, p=0.010). In addition, a simple linear regression analysis showed that the TSR might be an indicator for the PFS (B¡¾standard error, 244.54¡¾66.79; p=0.001). On univariate analysis, the sex, histologic type, smoking history and the number of prior chemotherapy regimens, were significant prognostic factors. On multivariate regression analysis, both the TSR (¥â=0.257, p=0.029) and adenocarcinoma (¥â=0.323, p=0.005) were independent prognostic factors for PFS.
Conclusion : Our results showed that the TSR might be an early prognostic indicator for PFS in patients receiving EGFR-TKI therapy.
Å°¿öµå
EGFR Tyrosine Kinase Inhibitor, Gefitinib, Carcinoma, Non-Small Cell Lung, Progression-Free Survival
KMID :
0383820150780040315
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Significant positive correlation between the TSR and PFS. Tumor shrinkage rate (TSR) might be an early prognostic indicator for progression-free survival (PFS) in patients receiving EGFR-TKI therapy